US Department of the Army to Grant Exclusive License to SciClone Pharmaceuticals for Hepatitis C Treatment

Summary

The US Department of the Army is set to grant an exclusive license to SciClone Pharmaceuticals, a California-based pharmaceutical company, for its patent applications related to a hepatitis C treatment, following a 60-day objection period.